Zura Bio (NASDAQ:ZURA) Announces Earnings Results, Misses Expectations By $0.02 EPS

Zura Bio (NASDAQ:ZURA) issued its earnings results on Tuesday. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.02), Zacks reports.

Zura Bio Trading Down 1.2%

Shares of NASDAQ ZURA opened at $5.56 on Wednesday. The company has a market cap of $527.54 million, a PE ratio of -5.10 and a beta of -0.02. The company has a 50-day moving average of $4.87 and a two-hundred day moving average of $5.41. Zura Bio has a 1-year low of $1.39 and a 1-year high of $7.44.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on ZURA shares. William Blair assumed coverage on Zura Bio in a research note on Wednesday, July 8th. They set an “outperform” rating for the company. Guggenheim reaffirmed a “buy” rating and issued a $20.00 target price (up from $15.00) on shares of Zura Bio in a report on Wednesday. Wedbush reaffirmed an “outperform” rating and set a $15.00 target price on shares of Zura Bio in a research report on Wednesday, July 1st. Wall Street Zen raised shares of Zura Bio from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 1st. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Zura Bio in a report on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Zura Bio has a consensus rating of “Moderate Buy” and an average price target of $12.60.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Squarepoint Ops LLC raised its stake in Zura Bio by 34.6% during the 4th quarter. Squarepoint Ops LLC now owns 33,801 shares of the company’s stock worth $177,000 after buying an additional 8,680 shares during the period. Bank of America Corp DE raised its holdings in shares of Zura Bio by 31.9% during the fourth quarter. Bank of America Corp DE now owns 41,222 shares of the company’s stock worth $103,000 after acquiring an additional 9,966 shares during the period. Scientech Research LLC bought a new position in Zura Bio during the 3rd quarter worth about $45,000. State Street Corp boosted its position in shares of Zura Bio by 8.3% during the fourth quarter. State Street Corp now owns 156,363 shares of the company’s stock worth $819,000 after buying an additional 12,000 shares during the period. Finally, Dimensional Fund Advisors LP bought a new stake in Zura Bio in the 4th quarter valued at approximately $123,000. Institutional investors own 61.14% of the company’s stock.

About Zura Bio

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.